Braeburn’s BRIXADI evidence package raises new questions for injectable buprenorphine adoption
Braeburn’s new BRIXADI data shows retention and dosing signals in opioid use disorder. Find out what it means for treatment strategy.
Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?
Purdue is gone, but its medicines remain. Knoa Pharma’s public health model now faces its hardest test: trust, access, and oversight.
SOLVD Health broadens AvertD access as FDA clears blood-based sample collection
FDA cleared blood-based collection for SOLVD Health’s AvertD. Find out why this could expand genetic opioid risk testing in surgical care.
Why AltaPointe’s ketamine-assisted protocol could reshape opioid withdrawal management
Find out how a low-dose ketamine protocol may help fentanyl users start buprenorphine faster and with less withdrawal discomfort.
Why Indivior’s Delaware redomiciliation matters more than a corporate address change
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.
Indivior’s SUBLOCADE shows stronger outcomes in high-frequency fentanyl users: What this changes for opioid use disorder treatment in 2026
Indivior’s new data shows SUBLOCADE 300 mg may improve outcomes in fentanyl users with OUD. Find out what this means for future treatment.